Why the study?
Do Direct Oral Anticoagulants (DOACs) improve efficacy and safety compared to Low Molecular Weight Heparin (LMWH) in cancer patients with venous thromboembolism?
Do Direct Oral Anticoagulants (DOACs) improve efficacy and safety compared to Low Molecular Weight Heparin (LMWH) in cancer patients with venous thromboembolism?
DOACs offer an effective and more convenient alternative to LMWH for cancer-associated VTE, but require careful patient selection due to bleeding risks in specific cancer types and drug interactions.
May support DOAC use in cancer-associated VTE; leaves open optimal agent selection in high-bleeding-risk subgroups.
DOACs); Gastrointestinal (GI); Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE) Cancer patients have an increased risk of venous thromboembolism (VTE) as well as bleeding. For many years Low Molecule Heparin (LMHW) remained standard of care for these patients. Recently Direct Oral Anticoagulants (DOACs) have shown similar efficacy and safety in large randomised control trials. Data from four recent trials done in cancer patients have highlighted importance of the DOACs in cancer patients. DOACs have been found to be simpler to administer with better compliance among cancer patients. However, there are several issues surrounding prescribing DOACs in these patients. Some of them are related to drug-to-drug interactions and others to an increased risk of bleeding in mucosal cancers of gastrointestinal (GI) and urothelial tracts.
No takes yet. Share an insight, caveat, or question.
Shahid Gilani (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: